Proffered Paper 2 - Gynaecological cancers

LINK to Proffered Paper 2 - Gynaecological cancers

LINK to STREAM (needs an ESMO registration)

LBA31 - Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

The abstract concludes: Atezo did not significantly improve PFS in the ITT or PD-L1+ population. The combination was generally well tolerated with manageable AEs. Exploratory biomarker subgroup analyses are ongoing.

 

805O - ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment

The abstract concludes: The final analysis for ICON8 confirms that, although weekly dose-dense chemotherapy is a safe alternative to q3w chemotherapy and can be delivered successfully in first-line EOC treatment, it does not significantly improve PFS or OS.

Read also the ESMO Daily Reporter News: 

Ovarian Cancer: First-line Dose-dense Chemotherapy is Not Superior to Standard 3-weekly Chemotherapy

 

LBA32 - Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study

The abstract concludes: Tisotumab vedotin demonstrated durable, clinically meaningful activity in a broad patient population, with a manageable and tolerable safety profile. Tisotumab vedotin has the potential to be a new therapy for patients with r/mCC.

 

807O - Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)

The abstract concludes: Nivolumab did not improve OS compared with GEM/PLD in patients with platinum-resistant ovarian cancer.